Literature DB >> 28775524

QUANTIFICATION OF EXERCISE TOLERANCE IN CONGESTIVE HEART FAILURE AND ROLE OF ACE INHIBITORS.

P K Hasija1, S D Karloopia2, B N Shahi3, S S Chauhan4.   

Abstract

A prospective randomised controlled trial with captopril/enalapril was carried out on 25 patients with congestive heart failure (CHF) of various aetiologies in NYHA Class II &amp; III to study the effect of Ace inhibitors on exercise tolerance. The control group (Gp-A) comprising of 12 patients received conventional treatment (digitalis and diuretics) and the test group (Gp-B) with 13 patients were in addition given captopril/enalapril as tolerated. They were followed up for a mean period of 101.6+50.6 days (approx 3 months). Ten patients from each group could complete the study. The exercise testing was done on treadmill using a suitable protocol and end-points, at the beginning and end of study. None of the clinical and noninvasive parameters showed significant difference, however the mean exercise duration in Group A improved from 7.84+3.34 to 9.2 +3.16 minute (P <0.05) and in Group B increased from 7.91+4.6 to 10. 92+4.66 minute (p < 0.001). On comparing the benefits of the two groups the difference was statistically significant (P < 0.05). It is concluded that Ace inhibitor improves the exercise tolerance in CHF and the benefit is evident despite any improvement in clinical and noninvasive indices of left ventricular function.

Entities:  

Keywords:  Ace-inhibitor; Exercise capacity; Heart failure

Year:  2017        PMID: 28775524      PMCID: PMC5531643          DOI: 10.1016/S0377-1237(17)30598-1

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  14 in total

1.  Captopril in congestive cardiac failure.

Authors:  N P Misra; P C Manoria; H H Trivedi; Y Mehrotra; P Pandey
Journal:  J Assoc Physicians India       Date:  1986-11

2.  Captopril therapy in chronic congestive heart failure.

Authors:  B S Yadav; U A Kaul; S Manoharan; V K Bahl; C M Khanna; M Khalilullah
Journal:  Indian Heart J       Date:  1985 Nov-Dec

3.  Clinical assessment and follow-up of functional capacity in patients with chronic congestive cardiomyopathy.

Authors:  R Engler; R Ray; C B Higgins; C McNally; W H Buxton; V Bhargava; R Shabetai
Journal:  Am J Cardiol       Date:  1982-06       Impact factor: 2.778

4.  Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.

Authors:  T B Levine; J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

5.  Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure.

Authors:  N Topic; B Kramer; B Massie
Journal:  Am Heart J       Date:  1982-11       Impact factor: 4.749

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.

Authors:  D B Northridge; E Rose; E D Raftery; A Lahiri; A T Elder; T R Shaw; E Henderson; H J Dargie
Journal:  Eur Heart J       Date:  1993-03       Impact factor: 29.983

8.  Comparison of lisinopril versus digoxin for congestive heart failure during maintenance diuretic therapy. The Lisinopril-Digoxin Study Group.

Authors:  J Herlitz
Journal:  Am J Cardiol       Date:  1992-10-08       Impact factor: 2.778

9.  Paradox of improved exercise but not resting hemodynamics with short-term prazosin in chronic heart failure.

Authors:  S A Rubin; K Chatterjee; H J Gelberg; T A Ports; B H Brundage; W W Parmley
Journal:  Am J Cardiol       Date:  1979-04       Impact factor: 2.778

10.  Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. The Cilazapril-Captopril Multicenter Group.

Authors: 
Journal:  Cardiology       Date:  1995       Impact factor: 1.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.